PE20200339A1 - Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida - Google Patents

Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida

Info

Publication number
PE20200339A1
PE20200339A1 PE2019002393A PE2019002393A PE20200339A1 PE 20200339 A1 PE20200339 A1 PE 20200339A1 PE 2019002393 A PE2019002393 A PE 2019002393A PE 2019002393 A PE2019002393 A PE 2019002393A PE 20200339 A1 PE20200339 A1 PE 20200339A1
Authority
PE
Peru
Prior art keywords
acetamido
pyrrolidine
butyl
carboxamide
preparing
Prior art date
Application number
PE2019002393A
Other languages
English (en)
Inventor
Zandt Michael Van
Jennifer L Savoy
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of PE20200339A1 publication Critical patent/PE20200339A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/22Separation; Purification; Stabilisation; Use of additives
    • C07C231/24Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/20Esters of monothiocarboxylic acids
    • C07C327/22Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Referido a un metodo para preparar (3R,4S)-3-acetamido-4-alil-N-(terc-butil)pirrolidina-3-carboxamida racemica y (3S,4R)-3-acetamido-4-alii-N-(terc- butil)pirrolidina-3-carboxamida usando cristalizacion selectiva con acidos carboxilicos quirales; a partir de un compuesto de amina de formula I, donde X es O, S o NRe; Ra es H, alquilo inferior, entre otros; Rb es -CH2CH=CH2, -CH2CH2CH2Z1, entre otros; Rc y Rd son independientemente H, alquilo inferior, sililo, entre otros; Re es H o alquilo inferior; Z1 es halogeno, sulfonato de alquilo, entre otros.
PE2019002393A 2017-05-12 2018-05-11 Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida PE20200339A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505282P 2017-05-12 2017-05-12
PCT/US2018/032407 WO2018209290A1 (en) 2017-05-12 2018-05-11 Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

Publications (1)

Publication Number Publication Date
PE20200339A1 true PE20200339A1 (es) 2020-02-14

Family

ID=62387001

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002393A PE20200339A1 (es) 2017-05-12 2018-05-11 Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida

Country Status (21)

Country Link
US (3) US10494339B2 (es)
EP (1) EP3621954B1 (es)
JP (1) JP2020519583A (es)
KR (1) KR20200008578A (es)
CN (1) CN110709383A (es)
AU (1) AU2018265873A1 (es)
BR (1) BR112019023582A2 (es)
CA (1) CA3062851A1 (es)
CL (1) CL2019003212A1 (es)
CO (1) CO2019013923A2 (es)
CR (1) CR20190562A (es)
EA (1) EA201992695A1 (es)
IL (2) IL278757B (es)
MA (1) MA48626A (es)
MX (1) MX2019013533A (es)
PE (1) PE20200339A1 (es)
PH (1) PH12019502505A1 (es)
SG (1) SG10201912946TA (es)
TW (1) TW201900609A (es)
WO (1) WO2018209290A1 (es)
ZA (1) ZA201908267B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2794006T3 (es) 2010-10-26 2020-11-17 Mars Inc Inhibidores de arginasa como agentes terapéuticos
JP2020519583A (ja) * 2017-05-12 2020-07-02 カリセラ バイオサイエンシズ,インコーポレイテッド (3r,4s)−3−アセトアミド−4−アリル−n−(tert−ブチル)ピロリジン−3−カルボキサミドの製造方法
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
US20220041630A1 (en) 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
CN113866289A (zh) * 2021-09-03 2021-12-31 上海凌凯医药科技有限公司 2,3-二苯甲酰氧基-4-二甲基氨基-4-氧代丁酸的手性分离检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
CA2415174A1 (en) 2000-07-06 2002-01-17 Thomas W. Bell Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
ES2729474T3 (es) 2009-01-26 2019-11-04 Univ Pennsylvania Inhibidores de la arginasa y métodos de uso
ES2729936T3 (es) 2010-04-22 2019-11-07 Mars Inc Inhibidores de arginasa y sus aplicaciones terapéuticas
ES2794006T3 (es) 2010-10-26 2020-11-17 Mars Inc Inhibidores de arginasa como agentes terapéuticos
CA2824599C (en) 2010-12-31 2020-03-10 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US9957271B2 (en) 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013158262A1 (en) 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
CN107405404A (zh) 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EP3368541B1 (en) 2015-10-30 2020-05-27 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
JP2020519583A (ja) * 2017-05-12 2020-07-02 カリセラ バイオサイエンシズ,インコーポレイテッド (3r,4s)−3−アセトアミド−4−アリル−n−(tert−ブチル)ピロリジン−3−カルボキサミドの製造方法

Also Published As

Publication number Publication date
US10906872B2 (en) 2021-02-02
US10494339B2 (en) 2019-12-03
WO2018209290A1 (en) 2018-11-15
JP2020519583A (ja) 2020-07-02
CO2019013923A2 (es) 2020-04-01
IL278757A (en) 2021-01-31
EP3621954A1 (en) 2020-03-18
IL285299A (en) 2021-09-30
CL2019003212A1 (es) 2020-02-21
CN110709383A (zh) 2020-01-17
EA201992695A1 (ru) 2020-05-15
US20180362459A1 (en) 2018-12-20
MX2019013533A (es) 2020-08-03
US11370754B2 (en) 2022-06-28
ZA201908267B (en) 2020-11-25
EP3621954B1 (en) 2022-03-09
BR112019023582A2 (pt) 2020-06-02
IL278757B (en) 2021-08-31
CR20190562A (es) 2020-03-04
TW201900609A (zh) 2019-01-01
SG10201912946TA (en) 2020-02-27
US20200087255A1 (en) 2020-03-19
MA48626A (fr) 2020-03-18
PH12019502505A1 (en) 2020-07-13
US20210155589A1 (en) 2021-05-27
AU2018265873A1 (en) 2019-11-28
CA3062851A1 (en) 2018-11-15
KR20200008578A (ko) 2020-01-28

Similar Documents

Publication Publication Date Title
PE20200339A1 (es) Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
SG10201903532XA (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
PH12016502334A1 (en) Method for producing fused heterocyclic compound
PE20170143A1 (es) Benzimidazol-2-aminas como inhibidores de midh1
EA201891544A1 (ru) Ингибиторы простатического специфического мембранного антигена (псма) на основе мочевины для визуализации и лечения
EA201890751A1 (ru) Противогрибковые соединения и способы их получения
PE20211392A1 (es) Separacion enantiomerica de nicotina racemica mediante adicion de un enantiomero de acido tartarico o,o'-disustituido
EA201892245A1 (ru) Способ получения энантиомерно-обогащенных изоксазолиновых соединений - кристаллический толуольный сольват(s)-афоксоланера
EA201891642A1 (ru) Кристаллические формы ингибитора mdm2
EA201792503A1 (ru) Соль (s)-kck s-кетамина, соль (r)-kck s-кетамина и способы получения s-кетамина
EA201992421A1 (ru) Способ получения озанимода
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
EA201891770A1 (ru) Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
IN2014KN01030A (es)
PE20141579A1 (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2021002854A (es) Ciclacion enzimatica de acido homofarnesilico.
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
ATE551312T1 (de) Verfahren zur racematspaltung von zopiclon und zwischenprodukten
BR112015015880A2 (pt) processo para a produção do composto, composto de fórmula, preparação farmacêutica e compostos, composições, métodos e utilizações substancialmente inovadores
EA202190330A1 (ru) Способ получения полиморфной формы робенакоксиба
UA110995C2 (uk) Етинільні похідні як модулятори метаботропного глутаматного рецептора
MX2022002568A (es) Proceso para preparar (r)-4-aminoindano y amidas correspondientes.
ES2721446T3 (es) Método para producir un compuesto de éster del ácido ciclopropano carboxílico ópticamente activo, un complejo de cobre asimétrico y un compuesto de salicilidenoaminoalcohol ópticamente activo
PE20170706A1 (es) Derivados del acido abscisico sustituido en 3'
ATE360006T1 (de) Verfahren zur racematspaltung von nefopam